$121 Million is the total value of Casdin Capital, LLC's 25 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | Sell | SAGE THERAPEUTICS INC | $13,250,000 | +8.0% | 259,500 | -2.6% | 10.94% | +10.1% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $10,036,000 | -32.7% | 240,500 | -14.9% | 8.29% | -31.4% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $6,858,000 | -19.5% | 244,500 | -14.8% | 5.66% | -17.9% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $6,242,000 | -15.4% | 510,000 | -18.4% | 5.16% | -13.7% |
| EPZM | Sell | EPIZYME INC | $3,328,000 | +14.6% | 275,000 | -6.8% | 2.75% | +16.9% |
| EDIT | Sell | EDITAS MEDICINE INC | $1,055,000 | -8.4% | 65,000 | -23.9% | 0.87% | -6.6% |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -33,000 | -100.0% | -0.98% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -195,000 | -100.0% | -0.99% | – |
| IBB | Exit | ISHARES TRnasdq biotec etf | $0 | – | -5,000 | -100.0% | -1.17% | – |
| MDGN | Exit | MEDGENICS INC | $0 | – | -375,000 | -100.0% | -1.69% | – |
| GHDX | Exit | GENOMIC HEALTH INC | $0 | – | -90,000 | -100.0% | -2.11% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -155,000 | -100.0% | -2.33% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -110,000 | -100.0% | -3.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.